Clinical trials: Cisplatin, completed
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is commonly observed in southern China, particularly in the Pearl River delta area and the Xijiang River basin in the Guangdong and Guangxi provinces, with an incidence rate as high as 25-50 per…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Cancer
- Trial name
- NCT04004871
- Testing
- Nab-paclitaxel, Cisplatin and Fluorouracil, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Peritoneal Neoplasms, Neoplasm Metastasis
HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
In this registry study the investigators will collect data about patients' disease, treatment, and response to treatment to include in both our local and national databases.
- Conditions
- Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
- Trial name
- NCT02082886
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Edward-Elmhurst Health System
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination…
- Trial name
- NCT05156970
- Testing
- Camrelizumab, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Osteosarcoma
ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities
Post-authorization, observational, multicenter and prospective study in patients between 2 and 30 years old diagnosed with non-metastatic high-grade osteosarcoma of the extremities.
- Trial name
- NCT04383288
- Where
- 17 sites in Spain
- Volunteers
- 115 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Non Small Cell Lung Cancer
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
This study mainly to observe the anti angiogenic drugs Endostatin (Endostar) combined with vinorelbine and Cisplatin (NP) as neoadjuvant therapy in patients with non small cell lung cancer clinical efficiency and safety.
- Trial name
- NCT02497118
- Testing
- Endostatin, Vinorelbine, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Melanoma (Skin)
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Breast Cancer, Melanoma (Skin), Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003690
- Testing
- alvocidib, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer.
- Conditions
- PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
- Trial name
- NCT00980460
- Testing
- Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride
- Where
- 209 sites in United States, Australia and 4 more
- Volunteers
- 236 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Chemotherapy and Radiation Following Pancreatic Surgery
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.
- Trial name
- NCT00660270
- Testing
- Pancreatic Surgery, Radiation therapy, Cisplatin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Head and Neck Cancer
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
The purpose of this study is to determine the highest dose of a ABI-007 that can be given with cisplatin and 5-fluorouracil without causing intolerable side effects in patients with advanced head and neck cancer.
- Trial name
- NCT00731380
- Testing
- ABI-007
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Advanced Tumors
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical…
- Trial name
- NCT04151810
- Testing
- CDP1, TIP chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Ovarian Neoplasms
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer.
- Trial name
- NCT00539669
- Testing
- Docetaxel
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Sanofi
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00002522
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Temple University
Melanoma, Skin Cancer
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide.
- Trial name
- NCT00885534
- Testing
- Cisplatin, Vinblastine, Temozolomide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Uterine Cervical Neoplasms, Squamous Cell Carcinoma
The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment.
- Conditions
- Uterine Cervical Neoplasms, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Adenosquamous
- Trial name
- NCT02394652
- Testing
- Metformin, Cisplatin, FAZA
- Where
- 5 sites in Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Neoplasms
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
Background: AZD2281 is an experimental drug in a class of agents called PARP inhibitors. PARP is a protein that is involved in repairing DNA damage; PARP inhibitors interfere with that process.
- Trial name
- NCT00678132
- Testing
- AZD 2281, Cisplatin, Gemcitabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Patients whose pancreatic cancers have defects in the BRCA/Fanconi DNA repair pathway or other defects in homologous repair will have cancers that respond to olaparib when given in combination with the DNA damaging agents…
- Trial name
- NCT01296763
- Testing
- Irinotecan, Cisplatin, Olaparib (for levels 1 and 5)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Pleural Mesothelioma
Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
Combination of gemcitabine-cisplatin was one of the most effective chemotherapy treatment in mesothelioma patients. However, median survival of this patient group was only about 12 months.
- Trial name
- NCT01243632
- Testing
- Prolonged 6-hr infusion of gemcitabine
- Where
- Slovenia
- Volunteers
- 78 people
- Sponsor
- Institute of Oncology Ljubljana
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.